SynAct Pharma has carried out a primary issuance of shares of approximately SEK 80 million at a subscription price of SEK 50 per share. The subscription price was determined through an accelerated bookbuilding procedure.
SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company intends to use the proceeds from the primary issue to reach the already announced milestones for its phase IIa studies in Rheumatoid Arthritis (RA), Nephrotic Syndrome and Covid-19 (ARDS), and be able to prepare for and complete a phase IIb study in RA.
ABG Sundal Collier acted as Sole Manager and Bookrunner. Baker McKenzie acted as legal advisor to ABG Sundal Collier. Joakim Falkner and Ian Gulam from Baker McKenzie's Capital Markets team in Stockholm were involved in the transaction.